Study of Tetrathiomolybdate in Patients With Wilson Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

OBJECTIVES:

Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborator: University of Michigan
• Treatments: Molybdenum; Tetrathiomolybdate; Trientine

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• Wilson disease presenting with neurologic or psychiatric symptoms

• No concurrent seizure activity

• No white matter lesions on brain magnetic resonance imaging

--Prior/Concurrent Therapy--

• No more than 2 weeks of prior therapy

• No penicillamine or trientine for longer than 2 weeks

--Patient Characteristics--

• Hepatic: No severe hepatic failure

• Other: No psychiatric or medical contraindication to protocol therapy

• Not pregnant